Emerging role for antioxidant therapy in protection against diabetic cardiac complications: Experimental and clinical evidence for utilization of classic and new antioxidants

Current Cardiology Reviews

Volumn 4, Issue 4, 2008, Pages 259-268

  Hill, Michael F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Diabetes mellitus; Diabetic cardiomyopathy; Heart failure; Myocardial infarction; Oxidative stress

Indexed keywords

3,4 DIHYDRO 4,4 DIMETHYL 1,3 BENZOSELENAZINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CARDIOVASCULAR AGENT; GLUTATHIONE; METALLOTHIONEIN; PLACEBO; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; RESVERATROL; TEMPOL; UNCLASSIFIED DRUG; ZINC;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATALYSIS; CELL DAMAGE; CELL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TREATMENT DURATION; VASCULAR DISEASE;

EID: 65649090962     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308786349453     Document Type: Review

References (112)

1. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-41.
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S14-21.
3. Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996; 28: 1661-9.
4. Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001; 24: 1422-7.
5. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31-7.
6. Solomon SD, St John Sutton M, Lamas GA, et al. Survival And Ventricular Enlargement (SAVE) Investigators. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002; 106: 1251-5.
7. Melchior T, Gadsboll N, Hildebrandt P, Kober L, Torp-Pedersen C. Clinical characteristics, left and right ventricular ejection fraction, and long-term prognosis in patients with non-insulin-dependent diabetes surviving an acute myocardial infarction. Diabet Med 1996; 13: 450-6.
8. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997; 126: 296-306.
9. Behar S, Boyko V, Reicher-Reiss H, Goldbourt U. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Am Heart J 1997; 133: 290-6.
10. Marwick TH. Diabetic heart disease. Heart 2006; 92: 296-300.
11. Kamalesh M. Heart failure in diabetes and related conditions. J Card Fail 2007; 13: 861-73.
12. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
13. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK. Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem 1996; 160-161: 283-8.
14. Nishio Y, Kashiwagi A, Taki H, et al. Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 1998; 47: 1318-25.
15. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002; 51: 174-81.
16. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001; 1: 181-93.
17. Penckofer S, Schwertz D, Florczak K. Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. J Cardiovasc Nurs 2002; 6: 68-85.
18. Marra G, Cotroneo P, Pitocco D, et al. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care 2002; 25: 370-5.
19. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
20. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet 1996; 347: 781-6.
21. Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3) Am J Cardiol 1996; 77: 232-6.
22. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-55.
23. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-60.
24. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 56-65.
25. Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000; 248: 377-86.
26. Hodis HN, Mack WJ, LaBree L, et al. VEAPS Research Group. VEAPS Research Group: Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002; 106: 1453-9.
27. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK. Free radicals and the heart. J Pharmacol Toxicol Methods 1993; 30: 55-67.
28. Singal PK, Petkau A, Gerrard JM, Hrushovetz S, Foerster J. Free radicals in health and disease. Mol Cell Biochem 1988; 84: 121-2.
29. Singal PK, Kirshenbaum LA. A relative deficit in antioxidant reserve may contribute in cardiac failure. Can J Cardiol 1990; 6: 47-9.
30. Weiss SJ. Oxygen, ischemia and inflammation. Acta Physiol Scand Suppl 1986; 548: 9-37.
31. Lawrence RA, Burk RF. Species, tissue and subcellular distribution of non Se-dependent glutathione peroxidase activity. J Nutr 1978; 108: 211-5.
32. Packer L. Vitamin E is nature's master antioxidant. Sci Am Sci Med 1994; 54-63.
33. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983; 161: 391-401.
34. Singal PK, Tong JG. Vitamin E deficiency accentuates adriamycin-induced cardiomyopathy and cell surface changes. Mol Cell Biochem 1988; 84: 163-71.
35. Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 1990; 30: 603-31.
36. Ferrari R, Ceconi C, Curello S, Cargnoni A, Medici D. Oxygen free radicals and reperfusion injury; the effect of ischaemia and reperfusion on the cellular ability to neutralise oxygen toxicity. J Mol Cell Cardiol 1986; 18 (Suppl 4): 67-9.
37. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Mol Cell Biochem 1995; 147: 77-81.
38. Gupta M, Singal PK. Time course of structure, function, and metabolic changes due to an exogenous source of oxygen metabolites in rat heart. Can J Physiol Pharmacol 1989; 67: 1549-59.
39. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998; 40: 239-47.
40. Gillery P, Monboisse JC, Maquart FX, Borel JP. Glycation of proteins as a source of superoxide. Diabete Metab 1988; 14: 25-30.
41. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245: 243-50.
42. Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990; 39: 1420-4.
43. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996; 97:1422-8.
44. Jain SK, Levine SN. Elevated lipid peroxidation and vitamin Equinone levels in heart ventricles of streptozotocin-treated diabetic rats. Free Radic Biol Med 1995; 18: 337-41.
45. Gutteridge JM, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1990; 15: 129-35.
46. Yeo HC, Helbock HJ, Chyu DW, Ames BN. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 1994; 220: 391-6.
47. Roberts LJ 2nd, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1997; 1345: 121-35.
48. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-7.
49. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-800.
50. Delanty N, Reilly MP, Pratico D, et al. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 1997; 95: 2492-9.
51. Smith HM, Hamblin M, Hill MF. Greater propensity of diabetic myocardium for oxidative stress after myocardial infarction is associated with the development of heart failure. J Mol Cell Cardiol 2005; 39: 657-65.
52. Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 2007; 42: 884-95.
53. Hamblin M, Smith HM, Hill MF. Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-isoprostaglandin F2alpha and oxidized glutathione. J Card Fail 2007; 13: 884-92.
54. Santini SA, Marra G, Giardina B, et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 1997; 46: 1853-8.
55. Güzel S, Seven A, Satman I, Burçak G. Comparison of oxidative stress indicators in plasma of recent-onset and long-term type 1 diabetic patients. J Toxicol Environ Health A 2000; 59: 7-14.
56. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995; 44: 1054-8.
57. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 1981; 25: 373-8.
58. Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-isoprostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
59. Gopaul NK, Anggård EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz- Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995; 368: 225-9.
60. Collier A, Wilson R, Bradley H, Thomson JA, Small M. Free radical activity in type 2 diabetes. Diabet Med 1990; 7: 27-30.
61. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-8.
62. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298: 431-7.
63. Marfella R, Esposito K, Nappo F, et al. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004; 53: 2383-91.
64. Marfella R, Cacciapuoti F, Siniscalchi M, et al. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. Diabet Med 2006; 23: 974-81.
65. Matata BM, Galinanes M. Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide. J Thorac Cardiovasc Surg 2000; 120: 1-11.
66. Munteanu A, Zingg JM, Azzi A. Anti-atherosclerotic effects of vitamin E- myth or reality? J Cell Mol Med 2004; 8: 59-76.
67. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005; 25: 151-74.
68. Otero P, Bonet B, Herrera E, Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. Prevention with Vitamin E administration. Atherosclerosis 2005; 182: 259-65.
69. Hayek T, Kaplan M, Kerry R, Aviram M. Macrophage NADPH oxidase activation, impaired cholesterol fluxes, and increased cholesterol biosynthesis in diabetic mice: a stimulatory role for D-glucose. Atherosclerosis 2007; 195: 277-86.
70. Kang YJ. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 1999; 222: 263-73.
71. Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65: 238-309.
72. Sato M, Bremner I. Oxygen free radicals and metallothionein. Free Radic Biol Med 1993; 14: 325-37.
73. Cai L, Satoh M, Tohyama C, Cherian MG. Metallothionein in radiation exposure: its induction and protective role. Toxicology 1999; 132: 85-98.
74. Cai L, Klein JB, Kang YJ. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem 2000; 275: 38957-60.
75. Cai L, Cherian MG. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium- metallothioneins. Toxicol Lett 2003; 136: 193-8.
76. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48: 1688-97.
77. Cai L, Wang J, Li Y, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005; 54: 1829-37.
78. Song Y, Wang J, Li Y, et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes- induced cardiac injury. Am J Pathol 2005; 167: 17-26.
79. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002; 51: 174-81.
80. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes- induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003; 52: 777-83.
81. Ali MM, Frei E, Straub J, Breuer A, Wiessler M. Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. Toxicology 2002; 179: 85-93.
82. Satoh M, Naganuma A, Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci 2000; 67: 627-34.
83. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006; 113: 544-54.
84. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 1998; 138: 619-20.
85. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000; 47: 549-55.
86. Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, Das DK. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999; 27: 160-9.
87. Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720-9.
88. Lekli I, Szabo G, Juhasz B, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2008; 294: H859-66.
89. Moutet M, d'Alessio P, Malette P, Devaux V, Chaudière J. Glutathione peroxidase mimics prevent TNFalpha- and neutrophil-induced endothelial alterations. Free Radic Biol Med 1998; 25: 270-81.
90. Chaudière J, Moutet M, D'Alessio P. Antioxidant and antiinflammatory protection of vascular endothelial cells by new synthetic mimics of glutathione peroxidase. C R Seances Soc Biol Fil 1995; 189: 861-82.
91. Yoshida T, Watanabe M, Engelman DT, et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J Mol Cell Cardiol 1996; 28: 1759-67.
92. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2004; 109: 544-9.
93. Kesavulu MM, Rao BK, Giri R, Vijaya J, Subramanyam G, Apparao C. Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract 2001; 53: 33-9.
94. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype-and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005; 96: 435-41.
95. Blum S, Asaf R, Guetta J, et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. J Am Coll Cardiol 2007; 49: 82-7.
96. Thiemermann C, McDonald MC, Cuzzocrea S. The stable nitroxide, tempol, attenuates the effects of peroxynitrite and oxygen-derived free radicals. Crit Care Med 2001; 29: 223-4.
97. Nassar T, Kadery B, Lotan C, Da'as N, Kleinman Y, Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 2002; 436: 111-8.
98. Jagadeesha DK, Lindley TE, Deleon J, Sharma RV, Miller F, Bhalla RC. Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats. Am J Physiol Heart Circ Physiol 2005; 289: H1047-53.
99. Kaczmarczyk SJ, Andrikopoulos S, Favaloro J, et al. Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. J Mol Endocrinol 2003; 31: 449-59.
100. Kamide K, Rakugi H, Higaki J, et al. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 2002; 15: 66-71.
101. Ritchie RH, Quinn JM, Cao AH, et al. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 2007; 42: 1119-28.
102. Costacou T, Zgibor JC, Evans RW, Tyurina YY, Kagan VE, Orchard TJ. Antioxidants and coronary artery disease among individuals with type 1 diabetes: Findings from the Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 2006; 20: 387-94.
103. Levy AP, Gerstein HC, Miller-Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004; 27: 2767.
104. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008; 28: 341-7.
105. Marfella R, Cacciapuoti F, Siniscalchi M, et al. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. Diabet Med 2006; 23: 974-81.
106. Di Filippo C, Cuzzocrea S, Rossi F, Marfella R, D'Amico M. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev 2006; 24: 77-87.
107. Ye G, Metreveli NS, Donthi RV, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004; 53: 1336-43.
108. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006; 55: 798-805.
109. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113: 2943-6.
110. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 2006; 29: 1697-9.
111. Heinecke JW. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler Thromb Vasc Biol 2001; 21: 1261-4.
112. Roberts LJ 2nd, Oates JA, Linton MF, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 2007; 43: 1388-93.